N
Nathalie Laplace
Researcher at Lyon College
Publications - 8
Citations - 334
Nathalie Laplace is an academic researcher from Lyon College. The author has contributed to research in topics: Cancer & Common Terminology Criteria for Adverse Events. The author has an hindex of 5, co-authored 8 publications receiving 160 citations. Previous affiliations of Nathalie Laplace include Claude Bernard University Lyon 1.
Papers
More filters
Journal ArticleDOI
Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications
Mohammad Alyami,Martin Hübner,Fabian Grass,Fabian Grass,Naoual Bakrin,Laurent Villeneuve,Nathalie Laplace,Guillaume Passot,Olivier Glehen,Vahan Kepenekian +9 more
TL;DR: From the findings, PIPAC has been shown to be feasible and safe and can be considered as a treatment option for refractory, isolated peritoneal metastasis of various origins, however, its use in further indications needs to be validated by prospective studies.
Journal ArticleDOI
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable peritoneal metastasis from gastric cancer.
Mohammad Alyami,Pierre-Emmanuel Bonnot,Frederic Mercier,Nathalie Laplace,Laurent Villeneuve,Guillaume Passot,Naoual Bakrin,Vahan Kepenekian,Olivier Glehen +8 more
TL;DR: PIPAC with low-dose cisplatin and doxorubicin is safe and feasible in association with systemic chemotherapy for gastric PM and justify further clinical studies in this indication.
Journal ArticleDOI
Unresectable peritoneal metastasis treated by pressurized intraperitoneal aerosol chemotherapy (PIPAC) leading to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Mohammad Alyami,Frederic Mercier,Matthieu Siebert,Pierre-Emmanuel Bonnot,Nathalie Laplace,Laurent Villeneuve,Guillaume Passot,Olivier Glehen,Naoual Bakrin,Vahan Kepenekian +9 more
TL;DR: Complete CRS and HIPEC can be achieved in strictly selected patient with unresectable PM at diagnosis after repeated PIPAC session with palliative intent, as described in this study.
Journal ArticleDOI
Current practice of pressurized intraperitoneal aerosol chemotherapy (PIPAC): Still standardized or on the verge of diversification?
Olivia Sgarbura,Laurent Villeneuve,Mohammad Alyami,Naoual Bakrin,Juan José Torrent,Clarisse Eveno,Martin Hübner,Julio Abba,Adnane Afifi,Michael Bau Mortensen,G. Bharath,Aditi Bhatt,Jimmy Bok Yan So,Andreas Brandl,Wim Ceelen,Delia Cortes-Guiral,Thomas Courvoiser,Julien Coget,Ignace H. J. T. de Hingh,Jean-Baptiste Delhorme,Suryanarayana S.V. Deo,Andrea Di Giorgio,Frédéric Dumont,Cecilia Escayola,Anne-Cécile Ezanno,Johan Gagnière,Julio Galindo,Torben Glatz,Tarkan Jäger,Maximilian Jarra,Ninad Katdare,Vahan Kepenekian,Vladimir M. Khomyakov,Konstantinos Kothonidis,Nathalie Laplace,Vincent Lavoué,Kuno Lehmann,Craig Lynch,Sanket Mehta,Bogdan Moldovan,Aviram Nissan,Maciej Nowacki,David Orry,Gloria Ortega Pérez,Urs G. Pabst,Brice Paquette,Marius Paškonis,Pompiliu Piso,Marc Pocard,Beate Rau,Marc A. Reymond,Frédéric Ris,M. Robella,José Silvestre-Rodriguez,Shivendra Singh,S.P. Somashekhar,Claudio Soravia,Isabelle Sourrouille,Abelkader Taibi,Clemens B. Tempfer,Jared Torkington,Giuseppe Vizzielli,Wouter Willaert +62 more
TL;DR: Homogeneous treatment standards of new techniques are important to guarantee safe implementation and practice but also to allow comparison between cohorts and multi-center analysis of merged data including registries.
Journal ArticleDOI
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in association with systemic chemotherapy and bevacizumab, evaluation of safety and feasibility. A single center comparative study
Matthieu Siebert,Mohammad Alyami,Frederic Mercier,Colin Gallice,Laurent Villeneuve,Nathalie Laplace,Guillaume Passot,Naoual Bakrin,Olivier Glehen,Vahan Kepenekian +9 more
TL;DR: PIPAC associated with bevacizumab is feasible, safe and well tolerated and the potential oncologic benefit of the concomitant use of bev ACZumab and PIPAC remains to be evaluated.